ArticleOncotarget2016

The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.

Nikos Papakonstantinou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.